Recombinant factor VIIa (NovoSeven®) as a hemostatic agent
U Hedner - Seminars in hematology, 2001 - Elsevier
Recombinant activated factor VII (rFVIIa; NovoSeven®, Novo Nordisk, Denmark) induces
hemostasis in life-and limb-threatening bleeds and in major surgery of hemophilia A and B
patients, regardless of inhibitor titer. A total of more than 6,500 patients have been treated,
and NovoSeven has been administered in more than 180,000 standard doses. Experience
gained from these clinical situations suggests that NovoSeven should be administered as a
90-to 110-μg/kg bolus dose every second hour. Hemophilia patients with mild to moderate …
hemostasis in life-and limb-threatening bleeds and in major surgery of hemophilia A and B
patients, regardless of inhibitor titer. A total of more than 6,500 patients have been treated,
and NovoSeven has been administered in more than 180,000 standard doses. Experience
gained from these clinical situations suggests that NovoSeven should be administered as a
90-to 110-μg/kg bolus dose every second hour. Hemophilia patients with mild to moderate …
